Three persons were injured after a Delhi Transport Corporation (DTC) electric bus they were travelling in overturned in Delhi's Rohini Sector 15 area on Sunday morning.
"It's unfortunate to know that such an incident happened. The Delhi government is resolutely standing with the grieving family," according to the Delhi Government's Transport Department statement.
Delhi Chief Minister Arvind Kejriwal on Friday wrote a letter to Delhi's Home Minister Kailash Gahlot asking him to appoint civil defence volunteers as home guards and depute them as marshals in public transport buses.
"To encourage people to use public transport, aggregators of AC luxury buses will be given licenses to operate buses in the city. No standing passengers will be allowed on these buses. Bus seats can be reserved only using app & digital payments," CM Kejriwal said in a press conference.
Sunnyvale (California) [US], October 17: Synopsys, Inc. (Nasdaq: SNPS) and the Indian Institute of Technology Bombay (IIT Bombay) today announced the inauguration of the Synopsys Semiconductor Lab for Virtual Fab Solutions at IIT Bombay as part of the Department of Electrical Engineering und
The photograhs were sent to Whatsapp groups of labourers, shopkeepers, and RWAs(Resident Welfare Associations). In the meantime, the CCTV Camera trail revealed that the perpetrator along with the kidnapped child went through the streets of Allah Colony, Shri Ram Chowk reached at West Vinod N
According to the findings of a multicenter phase II clinical trial, treating people who have differentiated thyroid cancer (DTC), an advanced form of thyroid cancer that arises from thyroid follicular cells, with the targeted tyrosine kinase inhibitor (TKI) cediranib in addition to their tre
According to the findings of a multicenter phase II clinical trial, treating patients with differentiated thyroid cancer (DTC), an advanced form of thyroid cancer that arises from thyroid follicular cells, in addition to their treatment with the targeted tyrosine kinase inhibitor (TKI) cedir
According to the findings of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Centre, adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not improve outcomes in patients with differ